Literature DB >> 31082453

Targeting mitochondria to protect axons in progressive MS.

Graham Campbell1, Simon Licht-Mayer1, Don Mahad2.   

Abstract

Inflammatory demyelinating processes target the neuron, particularly axons and synapses, in multiple sclerosis (MS). There is a gathering body of evidence indicating molecular changes which converge on mitochondria within neurons in progressive forms of MS. The most reproducible changes are the increase in mitochondrial content within demyelinated axons and mitochondrial respiratory chain complex deficiency in neurons, which compromises the capacity to generate ATP. The resulting lack of ATP and the likely energy failure state and its coupling with an increase in demand for energy by the demyelinated axon, are particularly relevant to the long tracts such as corticospinal tracts with long projection axons. Recent work in our laboratory and that of our collaborators indicate the limited reflection of the mitochondrial changes within neurons in the experimental disease models. Enhancing the energy producing capacity of neurons to meet the increased energy demand of demyelinated axons is likely to be a novel neuroprotective strategy in progressive MS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Axon loss; Demyelination; Mitochondria; Neurodegeneration; Progressive multiple sclerosis

Year:  2019        PMID: 31082453     DOI: 10.1016/j.neulet.2019.05.012

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

Review 1.  Positron emission tomography in multiple sclerosis - straight to the target.

Authors:  Benedetta Bodini; Matteo Tonietto; Laura Airas; Bruno Stankoff
Journal:  Nat Rev Neurol       Date:  2021-09-20       Impact factor: 42.937

2.  Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis.

Authors:  Daniela Buonvicino; Giuseppe Ranieri; Sara Pratesi; Elisabetta Gerace; Mirko Muzzi; Daniele Guasti; Lorenzo Tofani; Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2020-04-18       Impact factor: 8.739

Review 3.  Mind the gap: from neurons to networks to outcomes in multiple sclerosis.

Authors:  Declan T Chard; Adnan A S Alahmadi; Bertrand Audoin; Thalis Charalambous; Christian Enzinger; Hanneke E Hulst; Maria A Rocca; Àlex Rovira; Jaume Sastre-Garriga; Menno M Schoonheim; Betty Tijms; Carmen Tur; Claudia A M Gandini Wheeler-Kingshott; Alle Meije Wink; Olga Ciccarelli; Frederik Barkhof
Journal:  Nat Rev Neurol       Date:  2021-01-12       Impact factor: 42.937

Review 4.  Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Iphigenia Kanara; Anastasios N Mavrakis; Julie Pernokas; Mark Pernokas; Carl A Pinkert; Whitney R Powers; Konstantina Sampani; Kosta Steliou; Demetrios G Vavvas; Robert J Zamboni; Krishna Kodukula; Xiaohong Chen
Journal:  Biores Open Access       Date:  2020-03-31

5.  Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress.

Authors:  Bimala Malla; Agustin Liotta; Helena Bros; Rebecca Ulshöfer; Friedemann Paul; Anja E Hauser; Raluca Niesner; Carmen Infante-Duarte
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.